Nasdaq
$4.59▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.79BShares out 3.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 5d agoPre-market26.10.20 21:006-KKey event#●●●#●●●
AlvotechBullish
Alvotech has received FDA approval for a new manufacturing process (Process 2.0) for its Humira biosimilar, SIMLANDI. This approval allows the company to more than double its drug substance output per batch at its Reykjavik facility, significantly enhancing manufacturing productivity.…more
$4.59+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Regular26.10.14 23:056-KKey event
Alvotech
Alvotech has submitted a regulatory application to the European Medicines Agency (EMA) for AVT29, a proposed biosimilar to Eylea 8 mg. This marks the first regulatory submission worldwide for an Eylea 8 mg biosimilar, filed as a line extension to the existing marketing authorization for Mynzepli.…more
$4.59+0.00%vs prev closeView filingShare - 10.7Regular26.10.07 23:166-KKey event
Alvotech
Alvotech has entered into a long-term strategic manufacturing partnership with LOTTE Biologics to produce multiple antibody biosimilar products. Through this agreement, Alvotech will utilize the Syracuse facility to expand its global manufacturing capacity and meet demand for its pipeline over the next ten years.…more
$4.59+0.00%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 17:30Bullish#●●●#●●●
Alvotech Receives FDA Approval for SIMLANDI Manufacturing Process, Doubling Output…more
Alvotech has received FDA approval for an enhanced manufacturing process for its biosimilar SIMLANDI, which more than doubles output per batch. This improvement increases production efficiency and capacity, allowing the company to better meet growing market demand.…more
$4.59+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Pre-market26.10.14 17:30
●●●●●●●● ●●●●● ●●●●●●
Alvotech has submitted a regulatory application for AVT29, a proposed biosimilar to Eylea 8mg, marking the first such filing worldwide. While the high-dose formulation offers potential for reduced treatment frequency, the product remains in the regulatory review phase.…more
$4.59+0.00%vs prev close - 10.6After-hours26.10.07 05:30
●●●●●●●● ●●●●● ●●●●●●
Alvotech has entered into a long-term strategic manufacturing partnership with LOTTE Biologics to produce biosimilar products at its Syracuse facility in New York. This agreement expands Alvotech's global manufacturing capacity and supports its ability to meet growing international demand.…more
$4.59+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report